[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pds Biotechnology Corp (PDSB)

Pds Biotechnology Corp (PDSB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 47,226
  • Shares Outstanding, K 55,816
  • Annual Sales, $ 0 K
  • Annual Income, $ -34,500 K
  • EBIT $ -29 M
  • EBITDA $ -27 M
  • 60-Month Beta 1.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.92
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.67
  • Most Recent Earnings $-0.13 on 05/13/26
  • Next Earnings Date 08/12/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 435.23% (+47.09%)
  • Historical Volatility 84.94%
  • IV Percentile 68%
  • IV Rank 32.58%
  • IV High 1,204.24% on 12/02/25
  • IV Low 63.55% on 12/16/25
  • Expected Move (DTE 9) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 168
  • Volume Avg (30-Day) 384
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 5,123
  • Open Int (30-Day) 6,102
  • Expected Range 0.8351 to 0.8351

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.13
  • Number of Estimates 2
  • High Estimate $-0.12
  • Low Estimate $-0.14
  • Prior Year $-0.21
  • Growth Rate Est. (year over year) +38.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8002 +4.36%
on 07/07/26
1.1500 -27.38%
on 06/10/26
-0.1849 (-18.13%)
since 06/05/26
3-Month
0.8002 +4.36%
on 07/07/26
1.5500 -46.12%
on 05/14/26
-0.0829 (-9.03%)
since 04/07/26
52-Week
0.5068 +64.78%
on 03/31/26
1.5500 -46.12%
on 05/14/26
-0.3849 (-31.55%)
since 07/07/25

Most Recent Stories

More News
PDS Biotechnology Q1 Earnings Call Highlights

PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce...

PDSB : 0.8351 (-1.30%)
PDS Biotechnology: Q1 Earnings Snapshot

PDS Biotechnology: Q1 Earnings Snapshot

PDSB : 0.8351 (-1.30%)
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update

Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...

PDSB : 0.8351 (-1.30%)
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results

PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.8351 (-1.30%)
PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial

78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35% ...

PDSB : 0.8351 (-1.30%)
PDS Biotechnology: Q4 Earnings Snapshot

PDS Biotechnology: Q4 Earnings Snapshot

PDSB : 0.8351 (-1.30%)
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs Conference Call and Webcast Today at 8:00 am Eastern Time PRINCETON,...

PDSB : 0.8351 (-1.30%)
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.8351 (-1.30%)
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.8351 (-1.30%)
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

NCI-Led Study Shows Median PFS of 9.6 Months  Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology...

PDSB : 0.8351 (-1.30%)

Business Summary

PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary...

See More

Key Turning Points

3rd Resistance Point 0.9148
2nd Resistance Point 0.8849
1st Resistance Point 0.8600
Last Price 0.8351
1st Support Level 0.8052
2nd Support Level 0.7753
3rd Support Level 0.7504

See More

52-Week High 1.5500
Fibonacci 61.8% 1.1515
Fibonacci 50% 1.0284
Fibonacci 38.2% 0.9053
Last Price 0.8351
52-Week Low 0.5068

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.